Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
MATTERHORN
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
- NCT04592913 ↗
- Active, not recruiting
- AstraZeneca
- Deep
We haven't built an HCP commentary report on MATTERHORN (durvalumab in Gastrointestinal Neoplasms) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on MATTERHORN so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 334 | |
| YouTube | 175 | |
| Podcasts | 121 | |
| Bluesky threads | 25 | |
| X videos | 13 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Gastrointestinal Neoplasms; Esophagogastric Junction
- Interventions
- Durvalumab; FLOT chemotherapy
- Arms
- Arm B · Placebo comparator
- Arm A · Experimental
- Enrollment
- 957
- Primary outcomes
- Event-free survival (EFS)
- Sponsor
- AstraZeneca
- Start
- Nov 17, 2020
- Primary completion
- Dec 20, 2024
- Results posted
- No
- Registry record
- NCT04592913 · updated Dec 24, 2025
Publications
linked from the registry- Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Bragagnoli AC, Garbaos G, Liberman M, Miron MLL, Smyth EC, Cheng LY, Robbins SH, Valeri N, Xynos I, Tabernero J; MATTERHORN investigators. Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet. 2026 Sep 9:S0140-6736(26)01254-7. doi: 10.1016/S0140-6736(26)01254-7. Online ahead of print. PubMed 42716074
- Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Garrido M, Oliveira SCS, Liberman M, Oliden VC, Smyth EC, Stein A, Bilici M, Alvarenga ML, Kozlov V, Rivera F, Kawazoe A, Serrano O, Heilbron E, Negro A, Kurland JF, Tabernero J; MATTERHORN Investigators. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. N Engl J Med. 2025 Jul 17;393(3):217-230. doi: 10.1056/NEJMoa2503701. Epub 2025 Jun 1. PubMed 40454643
- Chang X, Ge X, Zhang Y, Xue X. The current management and biomarkers of immunotherapy in advanced gastric cancer. Medicine (Baltimore). 2022 May 27;101(21):e29304. doi: 10.1097/MD.0000000000029304. PubMed 35623069
- Janjigian YY, Van Cutsem E, Muro K, Wainberg Z, Al-Batran SE, Hyung WJ, Molena D, Marcovitz M, Ruscica D, Robbins SH, Negro A, Tabernero J. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Future Oncol. 2022 Jun;18(20):2465-2473. doi: 10.2217/fon-2022-0093. Epub 2022 May 10. PubMed 35535555
- Cowzer D, Janjigian YY. Top advances in esophageal/gastroesophageal junction cancers in 2021. Cancer. 2022 May 15;128(10):1894-1899. doi: 10.1002/cncr.34140. Epub 2022 Feb 18. No abstract available. PubMed 35179774